Pub Date : 2025-12-01Epub Date: 2025-10-10DOI: 10.1016/j.jdiacomp.2025.109197
Qin Zhou, Hao Yang, Xi-shao Xie, Ren-ding Wang
Aims
The evidence regarding a relationship between gestational diabetes mellitus (GDM) and the risk of chronic kidney disease (CKD) in later life has been inconsistent. We systematically evaluated whether such an association exists.
Methods
We searched the PubMed, Embase, and Cochrane Library databases from their inception to 18 May 2025. Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated to assess the association between GDM and subsequent CKD.
Results
Eight articles involving 21,806,683 pregnant women were included in our meta-analysis. The overall risk of CKD in the GDM group was significantly higher than in the control group (OR = 1.79, 95 % CI = 1.16–2.78, P = 0.009). Further analyses restricted to high-quality studies (OR = 2.75, 95 % CI = 1.68–4.52, P < 0.01, I2 = 96.8 %) or to studies adjusting for key confounders (OR = 2.76, 95 % CI = 1.67–4.52, P = 0.001, I2 = 65.9 %) also demonstrated a significant association. Most subgroup analysis results were consistent with the overall findings.
Conclusions
This systematic review and meta-analysis support a significant association between GDM and future CKD risk, suggesting that GDM may serve as an early warning sign for renal disease. However, confidence in the results was reduced by the considerable heterogeneity and more work is needed to understand this variability.
目的：关于妊娠期糖尿病（GDM）与以后生活中慢性肾脏疾病（CKD）风险之间关系的证据一直不一致。我们系统地评估了这种关联是否存在。方法：我们检索了PubMed、Embase和Cochrane图书馆数据库，从它们建立到2025年5月18日。计算优势比（ORs）和95%置信区间（ci）来评估GDM和随后的CKD之间的关系。结果：我们的meta分析纳入了8篇涉及21,806,683名孕妇的文章。GDM组发生CKD的总风险显著高于对照组（OR = 1.79, 95% CI = 1.16-2.78, P = 0.009）。进一步的分析仅限于高质量研究（OR = 2.75, 95% CI = 1.68-4.52, P 2 = 96.8%）或调整了关键混杂因素的研究（OR = 2.76, 95% CI = 1.67-4.52, P = 0.001, I2 = 65.9%）也显示了显著的相关性。大多数亚组分析结果与总体结果一致。结论：本系统综述和荟萃分析支持GDM与未来CKD风险之间的显著关联，提示GDM可能作为肾脏疾病的早期预警信号。然而，对结果的信心由于相当大的异质性而降低，需要更多的工作来理解这种可变性。
{"title":"Gestational diabetes mellitus and the subsequent risk of chronic kidney disease: A systematic review and meta-analysis","authors":"Qin Zhou, Hao Yang, Xi-shao Xie, Ren-ding Wang","doi":"10.1016/j.jdiacomp.2025.109197","DOIUrl":"10.1016/j.jdiacomp.2025.109197","url":null,"abstract":"<div><h3>Aims</h3><div>The evidence regarding a relationship between gestational diabetes mellitus (GDM) and the risk of chronic kidney disease (CKD) in later life has been inconsistent. We systematically evaluated whether such an association exists.</div></div><div><h3>Methods</h3><div>We searched the PubMed, Embase, and Cochrane Library databases from their inception to 18 May 2025. Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated to assess the association between GDM and subsequent CKD.</div></div><div><h3>Results</h3><div>Eight articles involving 21,806,683 pregnant women were included in our meta-analysis. The overall risk of CKD in the GDM group was significantly higher than in the control group (OR = 1.79, 95 % CI = 1.16–2.78, <em>P</em> = 0.009). Further analyses restricted to high-quality studies (OR = 2.75, 95 % CI = 1.68–4.52, <em>P</em> < 0.01, I<sup>2</sup> = 96.8 %) or to studies adjusting for key confounders (OR = 2.76, 95 % CI = 1.67–4.52, <em>P</em> = 0.001, I<sup>2</sup> = 65.9 %) also demonstrated a significant association. Most subgroup analysis results were consistent with the overall findings.</div></div><div><h3>Conclusions</h3><div>This systematic review and meta-analysis support a significant association between GDM and future CKD risk, suggesting that GDM may serve as an early warning sign for renal disease. However, confidence in the results was reduced by the considerable heterogeneity and more work is needed to understand this variability.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109197"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145308181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-11-10DOI: 10.1016/S1056-8727(25)00274-0
{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00274-0","DOIUrl":"10.1016/S1056-8727(25)00274-0","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109221"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145526302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-11DOI: 10.1016/j.jdiacomp.2025.109195
Chao Zhao , Xin Lu , Xiaoling Deng , Wenbo Xia , Tingting Sun , Di Huo , Lili Shi
To evaluate the effect of Bifidobacterium subsp. lactis BLa80 on glycemic control and gut microbiota composition in patients with type 2 diabetes mellitus (T2DM), a randomized, placebo-controlled clinical trial was conducted in 80 patients. Participants were randomly assigned to receive either BLa80 supplementation or placebo (n = 40 per group) in addition to standard metformin therapy for 12 weeks. Fasting blood and stool samples were collected at baseline and at the end of the intervention. The results showed that BLa80 supplementation significantly reduced fasting blood glucose and high-density lipoprotein cholesterol (HDL-C) levels, while low-density lipoprotein cholesterol (LDL-C) levels were increased. Furthermore, BLa80 modulated the diversity and composition of the gut microbiota after 12 weeks of intervention. In conclusion, BLa80 supplementation may improve glycemic control and modulate the gut microbiota in patients with T2DM, suggesting its potential as an adjunctive therapy in diabetes management.
{"title":"The effects of Bifidobacterium animalis subsp. lactis BLa80 on glycemic control and gut microbiota in patients with T2DM: a randomized, double-blind, placebo-controlled trial","authors":"Chao Zhao , Xin Lu , Xiaoling Deng , Wenbo Xia , Tingting Sun , Di Huo , Lili Shi","doi":"10.1016/j.jdiacomp.2025.109195","DOIUrl":"10.1016/j.jdiacomp.2025.109195","url":null,"abstract":"<div><div>To evaluate the effect of <em>Bifidobacterium</em> subsp. <em>lactis</em> BLa80 on glycemic control and gut microbiota composition in patients with type 2 diabetes mellitus (T2DM), a randomized, placebo-controlled clinical trial was conducted in 80 patients. Participants were randomly assigned to receive either BLa80 supplementation or placebo (<em>n</em> = 40 per group) in addition to standard metformin therapy for 12 weeks. Fasting blood and stool samples were collected at baseline and at the end of the intervention. The results showed that BLa80 supplementation significantly reduced fasting blood glucose and high-density lipoprotein cholesterol (HDL-C) levels, while low-density lipoprotein cholesterol (LDL-C) levels were increased. Furthermore, BLa80 modulated the diversity and composition of the gut microbiota after 12 weeks of intervention. In conclusion, BLa80 supplementation may improve glycemic control and modulate the gut microbiota in patients with T2DM, suggesting its potential as an adjunctive therapy in diabetes management.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109195"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145322617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-17DOI: 10.1016/j.jdiacomp.2025.109200
J.M. Zubiria , E. Molina , E. Toledo , L. Forga , J. Hermida
Aims/hypothesis
The role of matrix metalloproteinase-10 (MMP-10) in the development of severe complications in patients with type 1 diabetes is not fully understood. The hypothesis is that elevated MMP-10 levels are associated with increased risk of severe complications and that genetic variants leading to reduced or non-functional MMP-10 may confer cardiovascular protection.
Methods
195 patients with type 1 diabetes were recruited between 2007 and 2010. Serum MMP-10 concentrations were measured at baseline, and participants were prospectively followed until 2020. The association between baseline MMP-10 levels and a composite endpoint of severe complications of diabetes was analysed. In addition, genetic analysis of the MMP10 gene was performed to identify mutations that can result in a non-functional MMP-10 and lead to cardiovascular protection.
Results
Participants in the highest quartile of MMP-10 levels had a threefold higher risk of reaching the composite endpoint compared to those in the lowest quartile (p = 0.038). Moreover, there was a common polymorphism rs17860955 (minor allele frequency: 12 %) that lead to a non-functional MMP-10. These variant carriers showed significantly lower MMP-10 concentration (457.8 ± 309.9 pg/ml vs 942.1 ± 519.6 pg/ml; p < 0.0001) and non-significantly lower composite endpoint events.
Conclusions
Low MMP-10 concentration is associated to protection against severe vascular complications in patients with type 1 diabetes. There is a frequent polymorphism (rs17860955) that leads to lower MMP-10 levels and may offer a degree of cardiovascular protection.
目的/假设：基质金属蛋白酶-10 （MMP-10）在1型糖尿病患者严重并发症发生中的作用尚不完全清楚。假设MMP-10水平升高与严重并发症的风险增加有关，基因变异导致MMP-10减少或无功能可能赋予心血管保护作用。方法：在2007 - 2010年间招募195例1型糖尿病患者。在基线时测量血清MMP-10浓度，并对参与者进行前瞻性随访至2020年。分析了基线MMP-10水平与糖尿病严重并发症的复合终点之间的关系。此外，对MMP10基因进行了遗传分析，以确定可能导致无功能MMP-10并导致心血管保护的突变。结果：MMP-10水平最高四分位数的参与者达到复合终点的风险是最低四分位数的参与者的三倍（p = 0.038）。此外，存在一个共同的多态性rs17860955（次要等位基因频率：12%），导致MMP-10无功能。这些变异携带者的MMP-10浓度显著降低（457.8±309.9 pg/ml vs 942.1±519.6 pg/ml）。结论：低MMP-10浓度与1型糖尿病患者严重血管并发症的预防有关。有一个常见的多态性（rs17860955）导致较低的MMP-10水平，并可能提供一定程度的心血管保护。
{"title":"Association of matrix metalloproteinase-10 levels and genetic variant rs17860955 with severe vascular complications in patients with type 1 diabetes: prospective cohort","authors":"J.M. Zubiria , E. Molina , E. Toledo , L. Forga , J. Hermida","doi":"10.1016/j.jdiacomp.2025.109200","DOIUrl":"10.1016/j.jdiacomp.2025.109200","url":null,"abstract":"<div><h3>Aims/hypothesis</h3><div>The role of matrix metalloproteinase-10 (MMP-10) in the development of severe complications in patients with type 1 diabetes is not fully understood. The hypothesis is that elevated MMP-10 levels are associated with increased risk of severe complications and that genetic variants leading to reduced or non-functional MMP-10 may confer cardiovascular protection.</div></div><div><h3>Methods</h3><div>195 patients with type 1 diabetes were recruited between 2007 and 2010. Serum MMP-10 concentrations were measured at baseline, and participants were prospectively followed until 2020. The association between baseline MMP-10 levels and a composite endpoint of severe complications of diabetes was analysed. In addition, genetic analysis of the <em>MMP10</em> gene was performed to identify mutations that can result in a non-functional MMP-10 and lead to cardiovascular protection.</div></div><div><h3>Results</h3><div>Participants in the highest quartile of MMP-10 levels had a threefold higher risk of reaching the composite endpoint compared to those in the lowest quartile (<em>p</em> = 0.038). Moreover, there was a common polymorphism rs17860955 (minor allele frequency: 12 %) that lead to a non-functional MMP-10. These variant carriers showed significantly lower MMP-10 concentration (457.8 ± 309.9 pg/ml vs 942.1 ± 519.6 pg/ml; <em>p</em> < 0.0001) and non-significantly lower composite endpoint events.</div></div><div><h3>Conclusions</h3><div>Low MMP-10 concentration is associated to protection against severe vascular complications in patients with type 1 diabetes. There is a frequent polymorphism (rs17860955) that leads to lower MMP-10 levels and may offer a degree of cardiovascular protection.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109200"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-15DOI: 10.1016/j.jdiacomp.2025.109193
A.H. Abdelhafiz , I. Siqueira , A.J. Sinclair
Frailty is a metabolically heterogeneous condition and therefore, frail older people with diabetes are metabolically diverse. Diversity is caused by the varying degrees of insulin resistance, determined by the variability in muscle mass/visceral fat ratio and the overall body weight. This creates a frailty spectrum with sarcopenic/obese at one end to malnourished anorexic individuals at the other end. The sarcopenic obese are likely to have increased insulin resistance and progression of the metabolic syndrome. On the other hand, the anorexic malnourished are likely to have decreased insulin resistance due to significant weight loss and regression of the metabolic syndrome. The current evidence showed benefits of SGLT-2 inhibitors and GLP-1RA in frail older people with diabetes, and these benefits increased with increasing frailty. However, the majority of the population who benefited from this therapy were either overweight or obese. There is no evidence of benefits of such therapy in the anorexic malnourished end of the frailty spectrum such as people residents in care homes who were likely excluded from clinical trials. As the sarcopenic obese frail individuals are likely to have high burden of atherosclerotic vascular disease, we suggest that triple therapy of metformin, SGLT-2 inhibitors and GLP-1RA to be initiated as first line therapy in this group of patients if tolerated. On the other hand, this therapy is better avoided in the malnourished frail individuals due to significant weight loss, high risk of adverse events and, due to regression of the metabolic syndrome, the cardiovascular benefits are uncertain.
{"title":"Criteria of frail older people with type 2 diabetes who are suitable for SGLT-2 inhibitors and GLP-1RA therapy","authors":"A.H. Abdelhafiz , I. Siqueira , A.J. Sinclair","doi":"10.1016/j.jdiacomp.2025.109193","DOIUrl":"10.1016/j.jdiacomp.2025.109193","url":null,"abstract":"<div><div>Frailty is a metabolically heterogeneous condition and therefore, frail older people with diabetes are metabolically diverse. Diversity is caused by the varying degrees of insulin resistance, determined by the variability in muscle mass/visceral fat ratio and the overall body weight. This creates a frailty spectrum with sarcopenic/obese at one end to malnourished anorexic individuals at the other end. The sarcopenic obese are likely to have increased insulin resistance and progression of the metabolic syndrome. On the other hand, the anorexic malnourished are likely to have decreased insulin resistance due to significant weight loss and regression of the metabolic syndrome. The current evidence showed benefits of SGLT-2 inhibitors and GLP-1RA in frail older people with diabetes, and these benefits increased with increasing frailty. However, the majority of the population who benefited from this therapy were either overweight or obese. There is no evidence of benefits of such therapy in the anorexic malnourished end of the frailty spectrum such as people residents in care homes who were likely excluded from clinical trials. As the sarcopenic obese frail individuals are likely to have high burden of atherosclerotic vascular disease, we suggest that triple therapy of metformin, SGLT-2 inhibitors and GLP-1RA to be initiated as first line therapy in this group of patients if tolerated. On the other hand, this therapy is better avoided in the malnourished frail individuals due to significant weight loss, high risk of adverse events and, due to regression of the metabolic syndrome, the cardiovascular benefits are uncertain.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109193"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-10DOI: 10.1016/j.jdiacomp.2025.109194
Srikanta Banerjee , Jagdish Khubchandani , Rafael Gonzales-Lagos
Background
Type 2 Diabetes (T2D) continues to be a major cause of morbidity and a leading cause of mortality in the United States. Also, anxiety ranks among the topmost common mental health problems in the U.S. While the burden of anxiety among individuals with T2D is well known, the long-term impact of anxiety among adults with T2D has not been well explored. Thus, the purpose of this national study was to ascertain the impact of anxiety on mortality among Americans with T2D.
Methods
Data from the U.S. National Health and Nutrition Examination Survey (years 2007–2012) were linked with mortality data from the National Death Index up to December 31st, 2019.
Results
A total of 14,137 adults (aged 50 years and older) were included in the study sample, with more than a tenth (12.8 %) having T2D and more than a fifth (22.6 %) having anxiety. The unadjusted hazard ratio (HR) for all-cause mortality risk among those with T2D was 2.08 (95 % confidence interval [CI], 1.83–2.35, p < 0.01) compared to those without T2D. In the adjusted analysis, the risk of all-cause mortality was highest among individuals with both anxiety and T2D [AHR = 1.81 (95 % CI 1.37–2.40, p < 0.01)] compared to those with anxiety or T2D alone.
Conclusions
Our analysis provides vital information on factors that could be helpful for interventions to reduce mortality risk among those with T2D and anxiety. Also, given the higher risk of mortality with co-occurring T2D and anxiety, collaborative healthcare practices should help with widespread screening for and treatment of anxiety among middle and older-age adults with Type 2 Diabetes.
背景2型糖尿病（T2D）仍然是美国发病率和死亡率的主要原因。此外，在美国，焦虑是最常见的心理健康问题之一。虽然T2D患者的焦虑负担是众所周知的，但焦虑对成人T2D患者的长期影响尚未得到很好的探讨。因此，这项全国性研究的目的是确定焦虑对美国T2D患者死亡率的影响。方法将美国国家健康与营养检查调查（2007-2012年）的数据与截至2019年12月31日的国家死亡指数的死亡率数据相关联。结果共有14137名成年人（50岁及以上）被纳入研究样本，其中超过十分之一（12.8%）患有T2D，超过五分之一（22.6%）患有焦虑症。T2D患者与非T2D患者相比，未调整的全因死亡风险风险比（HR）为2.08（95%可信区间[CI]， 1.83-2.35, p < 0.01）。在调整后的分析中，与单纯焦虑或T2D患者相比，同时患有焦虑和T2D患者的全因死亡风险最高[AHR = 1.81 (95% CI 1.37-2.40, p < 0.01)]。结论sour分析提供了有助于干预措施降低T2D合并焦虑患者死亡风险的重要信息。此外，考虑到并发T2D和焦虑的死亡率较高，协作医疗实践应该有助于广泛筛查和治疗中老年人2型糖尿病患者的焦虑。
{"title":"Diabetes, anxiety, and mortality risk among middle and older-aged Americans","authors":"Srikanta Banerjee , Jagdish Khubchandani , Rafael Gonzales-Lagos","doi":"10.1016/j.jdiacomp.2025.109194","DOIUrl":"10.1016/j.jdiacomp.2025.109194","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 Diabetes (T2D) continues to be a major cause of morbidity and a leading cause of mortality in the United States. Also, anxiety ranks among the topmost common mental health problems in the U.S. While the burden of anxiety among individuals with T2D is well known, the long-term impact of anxiety among adults with T2D has not been well explored. Thus, the purpose of this national study was to ascertain the impact of anxiety on mortality among Americans with T2D.</div></div><div><h3>Methods</h3><div>Data from the U.S. National Health and Nutrition Examination Survey (years 2007–2012) were linked with mortality data from the National Death Index up to December 31st, 2019.</div></div><div><h3>Results</h3><div>A total of 14,137 adults (aged 50 years and older) were included in the study sample, with more than a tenth (12.8 %) having T2D and more than a fifth (22.6 %) having anxiety. The unadjusted hazard ratio (HR) for all-cause mortality risk among those with T2D was 2.08 (95 % confidence interval [CI], 1.83–2.35, <em>p</em> < 0.01) compared to those without T2D. In the adjusted analysis, the risk of all-cause mortality was highest among individuals with both anxiety and T2D [AHR = 1.81 (95 % CI 1.37–2.40, p < 0.01)] compared to those with anxiety or T2D alone.</div></div><div><h3>Conclusions</h3><div>Our analysis provides vital information on factors that could be helpful for interventions to reduce mortality risk among those with T2D and anxiety. Also, given the higher risk of mortality with co-occurring T2D and anxiety, collaborative healthcare practices should help with widespread screening for and treatment of anxiety among middle and older-age adults with Type 2 Diabetes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109194"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarcopenia, characterized by a progressive decline in skeletal muscle mass and strength, is increasingly recognized as a major public health concern. Several epidemiological studies have reported that diabetes mellitus is associated with the risk of sarcopenia. The aim of this study is to investigate the association between serum glycated albumin (GA) levels and the risk of developing sarcopenia and dynapenia in a community-dwelling older Japanese population.
Methods
A total of 905 participants aged ≥65 years without sarcopenia at baseline were followed for 5 years. Serum GA levels were categorized into quartiles. Sarcopenia was defined by the Asian Working Group for Sarcopenia 2019 criteria, and dynapenia was defined as low grip strength or low gait speed. The odds ratios (ORs) of developing sarcopenia and dynapenia and the mean values of percent change of muscle indices with 95 % confidential intervals (CIs) were estimated by logistic regression analysis and analysis of covariance, respectively.
Results
During the follow-up, 73 participants developed sarcopenia. Higher serum GA levels were significantly associated with greater risks of developing sarcopenia (OR 2.65, 95 %CI 0.95–2.65 in the highest vs. the lowest quartile) and dynapenia (OR 4.15, 95 %CI 2.13–4.15). Higher serum GA levels were related to declines in grip strength and gait speed. This association remained significant even among participants without diabetes or with hemoglobin A1c of <6.0 %.
Conclusions
Higher serum GA is a significant risk factor for both sarcopenia and dynapenia, with a stronger association observed for dynapenia, even in the absence of diabetes.
背景：骨骼肌减少症，以骨骼肌质量和力量的逐渐下降为特征，越来越被认为是一个主要的公共卫生问题。一些流行病学研究报道，糖尿病与肌肉减少症的风险有关。本研究的目的是调查血清糖化白蛋白（GA）水平与社区居住的日本老年人发生肌肉减少症和运动障碍的风险之间的关系。方法：共有905名年龄≥65岁、基线时无肌肉减少症的参与者，随访5年。血清GA水平分为四分位数。肌少症是由亚洲肌少症工作组2019年标准定义的，而动力不足被定义为握力低或步态速度低。分别采用logistic回归分析和协方差分析估计发生肌肉减少症和动力不足的比值比（ORs）和95%置信区间（ci）下肌肉指数百分比变化的平均值。结果：在随访期间，73名参与者出现了肌肉减少症。较高的血清GA水平与发生肌肉减少症（最高四分位数比为2.65,95% CI 0.95-2.65）和运动障碍（OR 4.15, 95% CI 2.13-4.15）的风险显著相关。血清GA水平升高与握力和步态速度下降有关。结论：血清GA升高是肌肉减少症和运动障碍的重要危险因素，即使在没有糖尿病的情况下，运动障碍的相关性也更强。
{"title":"Association between serum glycated albumin and the risk of sarcopenia and dynapenia in a community-dwelling older Japanese population: the Hisayama Study","authors":"Toshiharu Ninomiya , Hidekazu Konishi , Emi Ueda , Satoko Sakata , Emi Oishi , Yoshihiko Furuta , Saori Ohmae , Hiroyuki Hoshiko , Norifumi Tateishi , Mao Shibata , Jun Hata","doi":"10.1016/j.jdiacomp.2025.109199","DOIUrl":"10.1016/j.jdiacomp.2025.109199","url":null,"abstract":"<div><h3>Background</h3><div>Sarcopenia, characterized by a progressive decline in skeletal muscle mass and strength, is increasingly recognized as a major public health concern. Several epidemiological studies have reported that diabetes mellitus is associated with the risk of sarcopenia. The aim of this study is to investigate the association between serum glycated albumin (GA) levels and the risk of developing sarcopenia and dynapenia in a community-dwelling older Japanese population.</div></div><div><h3>Methods</h3><div>A total of 905 participants aged ≥65 years without sarcopenia at baseline were followed for 5 years. Serum GA levels were categorized into quartiles. Sarcopenia was defined by the Asian Working Group for Sarcopenia 2019 criteria, and dynapenia was defined as low grip strength or low gait speed. The odds ratios (ORs) of developing sarcopenia and dynapenia and the mean values of percent change of muscle indices with 95 % confidential intervals (CIs) were estimated by logistic regression analysis and analysis of covariance, respectively.</div></div><div><h3>Results</h3><div>During the follow-up, 73 participants developed sarcopenia. Higher serum GA levels were significantly associated with greater risks of developing sarcopenia (OR 2.65, 95 %CI 0.95–2.65 in the highest vs. the lowest quartile) and dynapenia (OR 4.15, 95 %CI 2.13–4.15). Higher serum GA levels were related to declines in grip strength and gait speed. This association remained significant even among participants without diabetes or with hemoglobin A1c of <6.0 %.</div></div><div><h3>Conclusions</h3><div>Higher serum GA is a significant risk factor for both sarcopenia and dynapenia, with a stronger association observed for dynapenia, even in the absence of diabetes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109199"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-17DOI: 10.1016/j.jdiacomp.2025.109198
Adriana Wisniewski , Justin DeMonte , Angelica Cristello Sarteau , Angela Fruik , Ruth S. Weinstock , Anna R. Kahkoska
Objective
Characterize diabetes distress (DD) in older adults with type 1 diabetes (T1D) and explore associations with individual-level characteristics.
Research design & methods
Adults ≥65 years with T1D (n = 337; mean 70.7 years) were recruited from the T1D Exchange (08/27/2024–11/05/2024) to complete an electronic survey, including the Type 1 Diabetes Distress Assessment System. Univariable linear regressions were used to assess cross-sectional associations between DD and self-reported sociodemographic, clinical, and diabetes-related variables. Select variables were explored further using bar graphs of DD core and source scores.
Results
The median (IQR) DD core score was 1.75 (1.375–2.5), and 36.5 % of respondents had a clinically significant DD core score. DD was positively associated with being female (β = 0.37; 95 % CI: 0.20–0.55), higher HbA1c (β = 0.32; 95 % CI: 0.21–0.43), and an emergency room (ER) visit in the past year (β = 0.33; 95 % CI: 0.12–0.53). DD was negatively associated with longer T1D duration (β = −0.01; 95 % CI: −0.02 to −0.01). The most prominent sources of DD were financial, management, and complication worries, and the least prominent were interpersonal, shame, and resources.
Conclusions
In addition to known correlates of DD among individuals with T1D (e.g., HbA1c), this study revealed novel correlates of DD among older adults, including older age at diagnosis, at least one ER visit within the last 12 months, and shorter T1D duration. Limitations include self-reported variables, the cross-sectional nature, and a relatively homogeneous sample by race, high prevalence of technology use, and HbA1c levels largely at goal.
{"title":"Levels of diabetes distress and its sources among older adults with type 1 diabetes and relationships to diabetes duration","authors":"Adriana Wisniewski , Justin DeMonte , Angelica Cristello Sarteau , Angela Fruik , Ruth S. Weinstock , Anna R. Kahkoska","doi":"10.1016/j.jdiacomp.2025.109198","DOIUrl":"10.1016/j.jdiacomp.2025.109198","url":null,"abstract":"<div><h3>Objective</h3><div>Characterize diabetes distress (DD) in older adults with type 1 diabetes (T1D) and explore associations with individual-level characteristics.</div></div><div><h3>Research design & methods</h3><div>Adults ≥65 years with T1D (<em>n</em> = 337; mean 70.7 years) were recruited from the T1D Exchange (08/27/2024–11/05/2024) to complete an electronic survey, including the Type 1 Diabetes Distress Assessment System. Univariable linear regressions were used to assess cross-sectional associations between DD and self-reported sociodemographic, clinical, and diabetes-related variables. Select variables were explored further using bar graphs of DD core and source scores.</div></div><div><h3>Results</h3><div>The median (IQR) DD core score was 1.75 (1.375–2.5), and 36.5 % of respondents had a clinically significant DD core score. DD was positively associated with being female (β = 0.37; 95 % CI: 0.20–0.55), higher HbA1c (β = 0.32; 95 % CI: 0.21–0.43), and an emergency room (ER) visit in the past year (β = 0.33; 95 % CI: 0.12–0.53). DD was negatively associated with longer T1D duration (β = −0.01; 95 % CI: −0.02 to −0.01). The most prominent sources of DD were financial, management, and complication worries, and the least prominent were interpersonal, shame, and resources.</div></div><div><h3>Conclusions</h3><div>In addition to known correlates of DD among individuals with T1D (e.g., HbA1c), this study revealed novel correlates of DD among older adults, including older age at diagnosis, at least one ER visit within the last 12 months, and shorter T1D duration. Limitations include self-reported variables, the cross-sectional nature, and a relatively homogeneous sample by race, high prevalence of technology use, and HbA1c levels largely at goal.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109198"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-08-27DOI: 10.1016/j.jdiacomp.2025.109158
Steven James , Rebecca Barber , Jess Forster , Lindsay Sawatsky , Samantha Berry , Olive James , Kerrie Abel , Claire Trigg , Kim C. Donaghue , Maria E. Craig , Mahira Saiyed , Sheryl S. Salis , Jamie Wood , Willem Staels
Aims
Our review aimed to determine the prevalence of – and factors associated with – hearing loss, oral and olfactory disease, frozen shoulder, trigger finger, and hair loss in young adults with type 1 diabetes. These conditions were selected based on research team interests, existing literature, and group discussion.
Methods
We conducted a quantitative narrative review using a systematic process to identify cohort and cross-sectional studies involving young adults with type 1 diabetes (mean age 18–30 years). PubMed, CINAHL, and Cochrane were searched (January 2000–February 2024). Grey literature was not restricted, and quality appraisal was undertaken. Extracted data were synthesised and summarised narratively.
Results
The initial search found 3924 records and after title, abstract and full-text review, 19 records met inclusion criteria. Hearing loss prevalence ranged from 22.6 to 48.0 %, with age, diabetes duration, and systolic blood pressure identified as prominent associated features. For oral disease, peridontitis prevalence was 4.7 %, while alveolar bone loss ranged from 24.6 to 43.9 %; age was the primary associated factor. No eligible data were identified regarding frozen shoulder, trigger finger, or hair loss.
Conclusions
Further research is needed to characterize the prevalence and risk factors of atypical complications in type 1 diabetes. Clinical care should be guided by a robust understanding of these under-recognised comorbidities.
{"title":"Atypical complications and co-morbidities of type 1 diabetes in young adults","authors":"Steven James , Rebecca Barber , Jess Forster , Lindsay Sawatsky , Samantha Berry , Olive James , Kerrie Abel , Claire Trigg , Kim C. Donaghue , Maria E. Craig , Mahira Saiyed , Sheryl S. Salis , Jamie Wood , Willem Staels","doi":"10.1016/j.jdiacomp.2025.109158","DOIUrl":"10.1016/j.jdiacomp.2025.109158","url":null,"abstract":"<div><h3>Aims</h3><div>Our review aimed to determine the prevalence of – and factors associated with – hearing loss, oral and olfactory disease, frozen shoulder, trigger finger, and hair loss in young adults with type 1 diabetes. These conditions were selected based on research team interests, existing literature, and group discussion.</div></div><div><h3>Methods</h3><div>We conducted a quantitative narrative review using a systematic process to identify cohort and cross-sectional studies involving young adults with type 1 diabetes (mean age 18–30 years). PubMed, CINAHL, and Cochrane were searched (January 2000–February 2024). Grey literature was not restricted, and quality appraisal was undertaken. Extracted data were synthesised and summarised narratively.</div></div><div><h3>Results</h3><div>The initial search found 3924 records and after title, abstract and full-text review, 19 records met inclusion criteria. Hearing loss prevalence ranged from 22.6 to 48.0 %, with age, diabetes duration, and systolic blood pressure identified as prominent associated features. For oral disease, peridontitis prevalence was 4.7 %, while alveolar bone loss ranged from 24.6 to 43.9 %; age was the primary associated factor. No eligible data were identified regarding frozen shoulder, trigger finger, or hair loss.</div></div><div><h3>Conclusions</h3><div>Further research is needed to characterize the prevalence and risk factors of atypical complications in type 1 diabetes. Clinical care should be guided by a robust understanding of these under-recognised comorbidities.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109158"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-10-17DOI: 10.1016/S1056-8727(25)00239-9
{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00239-9","DOIUrl":"10.1016/S1056-8727(25)00239-9","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109186"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145320687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号